US FDA approves injectable version of Roche's multiple sclerosis therapy
Adds background throughout
Sept 12 (Reuters) -The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis.
The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
The approval for the subcutaneous, or under-the-skin, version of the therapy will help expand its use to treatment centers not equipped to handle intravenous therapies.
Ocrevus is used to treat patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Roche did not immediately respond to a Reuters' request seeking details on availability date and pricing of the injectable version.
Multiple sclerosis is a condition that occurs when the immune system attacks the brain and spinal cord.
Roche estimates that this disease affects more than 2.8 million people worldwide.
RMS is characterized by episodes of new or worsening signs or symptoms, followed by periods of recovery. PPMS causes gradual worsening of neurological symptoms and disability without relapses or remissions.
The subcutaneous version, Tecentriq Hybreza, is a 7-minute injection given twice a year, the same schedule as the previously approved intravenous infusion.
The approval was based on data from a late-stage study that showed Ocrevus as an under-the-skin injection was non-inferior to its intravenous version, as measured by blood levels over 12 weeks.
The injectable version also had a safety and efficacy profile similar to the IV formulation in patients with RMS and PPMS.
The subcutaneous formulation, which received marketing authorization from the European Commission in June, combines Ocrevus with Halozyme Therapeutics' HALO.O drug delivery technology, which allows the therapy to be rapidly dispersed and absorbed into the bloodstream.
Ocrevus is a monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to nerve cell damage.
More than 350,000 people with multiple sclerosis have been treated with Ocrevus IV globally, according to Roche. The IV formulation of Ocrevus recorded sales of 6.38 billion Swiss francs ($7.54 billion) in 2023.
Other approved treatments for RMS include Novartis' NOVN.S Kesimpta, which is given as an injection once a month, and Biogen's BIIB.O Tysabri — an IV infusion given every four weeks.
($1 = 0.8464 Swiss francs)
Reporting by Sneha S K,Sruthi Narasimha Chari and Urvi Dugar in Bengaluru; Editing by Shilpi Majumdar and Subhranshu Sahu
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
